{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=41",
    "query": {
      "intervention": "Saline (Placebo Control)",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 3529,
    "total_pages": 353,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T18:37:27.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00264732",
      "title": "A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uterine Cervical Dysplasia"
      ],
      "interventions": [
        {
          "name": "Amolimogene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 25 Years · Female only"
      },
      "enrollment_count": 251,
      "start_date": "2005-07",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2013-05-29",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264732"
    },
    {
      "nct_id": "NCT04238598",
      "title": "Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Pulse Radiofrequency",
          "type": "PROCEDURE"
        },
        {
          "name": "Standard of Care Intra- Articular Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Intra-Articular Injection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Center For Interventional Pain and Spine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2019-10-08",
      "completion_date": "2021-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 1,
      "location_summary": "Exton, Pennsylvania",
      "locations": [
        {
          "city": "Exton",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04238598"
    },
    {
      "nct_id": "NCT00476931",
      "title": "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2",
        "Diabetic Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "SB-509",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 91,
      "start_date": "2007-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • Lakewood, California • Lomita, California + 15 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00476931"
    },
    {
      "nct_id": "NCT06897202",
      "title": "A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity in Diabetes",
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "MET097 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 133,
      "start_date": "2025-03-14",
      "completion_date": "2026-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 29,
      "location_summary": "Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06897202"
    },
    {
      "nct_id": "NCT07487831",
      "title": "The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis (Eczema)",
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Sodium chloride tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-07-14",
      "completion_date": "2028-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07487831"
    },
    {
      "nct_id": "NCT02165202",
      "title": "Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2014-10",
      "completion_date": "2017-03-09",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 2,
      "location_summary": "Newark, New Jersey • The Bronx, New York",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165202"
    },
    {
      "nct_id": "NCT04537208",
      "title": "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "CoV2 preS dTM-AF03 (low-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AF03 (high-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AS03 (low-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AS03 (high-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM (high-dose) without adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% normal saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 441,
      "start_date": "2020-09-03",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04537208"
    },
    {
      "nct_id": "NCT04540185",
      "title": "A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19",
        "SARS (Severe Acute Respiratory Syndrome)",
        "SARS-CoV Infection",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Biological: oral polio vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparable Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NA-831",
          "type": "DRUG"
        },
        {
          "name": "Comparable Placebo of drug",
          "type": "DRUG"
        },
        {
          "name": "Combination of oral polio vaccine and NA-831",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Comparable Placebo of Oral Polio Vaccine and Placebo of drug",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3600,
      "start_date": "2020-11-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-09-09",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04540185"
    },
    {
      "nct_id": "NCT03425643",
      "title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 797,
      "start_date": "2018-04-24",
      "completion_date": "2026-10-15",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 51,
      "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03425643"
    },
    {
      "nct_id": "NCT00513240",
      "title": "Erythropoetin Neuroprotection for Neonatal Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congenital Heart Disease",
        "Hypoplastic Left Heart Syndrome",
        "Transposition of the Great Arteries",
        "Aortic Arch Hypoplasia or Interruption"
      ],
      "interventions": [
        {
          "name": "Erythropoetin",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "1 Day to 30 Days"
      },
      "enrollment_count": 62,
      "start_date": "2006-09",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-10-22T18:37:27.818Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00513240"
    }
  ]
}